key: cord-261471-3msk5ggc authors: Whyte, Martin B.; Vas, Prashanth; Heiss, Christian; Feher, Michael D. title: The contribution of diabetic micro-angiopathy to adverse outcomes in COVID-19 date: 2020-05-13 journal: Diabetes Res Clin Pract DOI: 10.1016/j.diabres.2020.108217 sha: doc_id: 261471 cord_uid: 3msk5ggc Increasing evidence points to endothelial cell dysfunction as a key pathophysiological factor in severe coronavirus disease-19 (COVID-19), manifested by platelet aggregation, microthrombi and altered vasomotor tone. This may be driven by direct endothelial cell entry by the virus, or indirectly by activated inflammatory cascade. Major risk groups identified for adverse outcomes in COVID-19 are diabetes, and those from the Black, Asian and ethnic minority (BAME) populations. Hyperglycaemia (expressed as glycated haemoglobin or mean hospital glucose) correlates with worse outcomes in COVID-19. It is not known whether hyperglycaemia is causative or is a surrogate marker - persistent hyperglycaemia is well known as an aetiological agent in microangiopathy. In this article, we propose that pre-existing endothelial dysfunction of microangiopathy, more commonly evident in diabetes and BAME groups, makes an individual vulnerable to the subsequent ‘endothelitis’ of COVID-19 infection. Increasing evidence points to endothelial cell dysfunction as a key pathophysiological factor in severe coronavirus disease-19 , manifested by platelet aggregation, microthrombi and altered vasomotor tone. This may be driven by direct endothelial cell entry by the virus, or indirectly by activated inflammatory cascade. Major risk groups identified for adverse outcomes in are diabetes, and those from the Black, Asian and ethnic minority (BAME) populations. Hyperglycaemia (expressed as glycated haemoglobin or mean hospital glucose) correlates with worse outcomes in COVID-19. It is not known whether hyperglycaemia is causative or is a surrogate marker -persistent hyperglycaemia is well known as an aetiological agent in microangiopathy. In this article, we propose that pre-existing endothelial dysfunction of microangiopathy, more commonly evident in diabetes and BAME groups, makes an individual vulnerable to the subsequent 'endothelitis' of COVID-19 infection. There is emerging understanding that coronavirus disease-19 (COVID-19) induced respiratory complications appear to have a distinct pattern that differs from typical adult respiratory distress syndrome (ARDS). It is characterised by a dissociation between relatively well-preserved lung mechanics and the severity of hypoxemia. [1] A possible explanation for the severe hypoxemia occurring in compliant lungs, is the loss of lung perfusion regulation and hypoxic vasoconstriction. Coagulation dysfunction also appears to be common in severe COVID-19,[2; 3] with fatal cases exhibiting diffuse microvascular thrombosis, suggesting a thrombogenic microangiopathy. [4] It is becoming increasingly recognised, therefore, that endothelial damage and pulmonary was up to 50% higher in patients with diabetes. [6] Furthermore, well-controlled blood glucose was associated with lower hospital mortality than poorly controlled glucose (hazard ratio 0.14). [6] Diabetes is characterised, not only by hyperglycaemia, but also endothelial dysfunction and microcirculatory impairment. [9] Microvascular disease (either retinopathy or nephropathy) is present in over one-third of newly-diagnosed patients with type-2 diabetes (T2D). [10] The consequences of endothelial dysfunction include dysregulation of vasodilation, fibrinolysis, and antiaggregation -classically leading to macrovascular disease -and may contribute to microvascular disease retinopathy, nephropathy and neuropathy. [10] However, evidence of microvascular dysfunction in one organ is a marker of systemic injury. It is increasingly recognised that there are microvascular pulmonary complications of diabetes ('diabetic lung'). [11] It has been suggested that reduced pulmonary diffusing capacity for carbon monoxide (DL CO ) [11; 12] may be attributed to vascular injury of pulmonary capillaries related to diabetic microangiopathy. [11; 13] Importantly, the functional impairment was directly related to the degree of glucose control (glycated haemoglobin -HbA 1c ) and the presence of diabetic microvascular complications including retinopathy, neuropathy, and microalbuminuria in a sex-specific manner. [11] The relationship of impaired gas exchange with diabetes was observed, even in those who had never smoked. [11] In these individuals, the pulmonary microvasculature may be poorly prepared to meet the challenge of COVID-19 infection. The Black, Asian and minority ethnic (BAME) community have suffered disproportionally from COVID-19. BAME, although only 13% of the United Kingdom population and a younger age distribution,[14] accounts for one third of all COVID-19 cases and 34% of critically-ill COVID-19 patients. [15; 16] The mechanisms underlying the disproportionate effect of COVID-19 infection on BAME patients remain incompletely understood. However, BAME groups have a disproportionally high prevalence of T2D [17] and disparities have been observed in diabetes control, monitoring and presence of microvascular complications in the BAME, compared to white population. [18] In this context, dysglycaemia (both HbA 1c and mean glucose) associating with adverse outcomes in COVID-19, may be surrogates for the presence and severity of underlying microvascular disease. [6] The prevalence of prediabetes among adults is approximately 38% and 35%, in the United States [17] and United Kingdom [19] respectively. Prediabetes is also over-represented in BAME population. In the UK, the hazard ratio for prediabetes in South Asians was 1.67 (1.12 to 2.50) and for Blacks 1.45 (0.92 to 2.27), compared to the white population. [19] Although it is alluring to think that people with prediabetes are protected from microvascular disease; early stages of retinopathy, nephropathy, and neuropathy have been reported in people with prediabetes, with a prevalence of up to 10%. [10; 20] Microvascular disease and endothelial dysfunction may underlie adverse outcomes in COVID-19 and may represent the pathophysiological key missing link that identifies susceptible populations and may require specific treatment. Analyses of data on patients with COVID-19 should include details of diabetes complications and age, to untangle the complex interaction between ethnicity, diabetes and COVID-19 outcomes. Covid-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation Endothelial cell infection and endotheliitis in COVID-19 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention Endothelial dysfunction in diabetes: the role of reparatory mechanisms Association between pre-diabetes and microvascular and macrovascular disease in newly diagnosed type 2 diabetes Diminished alveolar microvascular reserves in type 2 diabetes reflect systemic microangiopathy Cross-section study of pulmonary function in patients with insulin-dependent diabetes mellitus Abnormalities of pulmonary function in patients with non-insulin-dependent diabetes mellitus Are some ethnic groups more vulnerable to COVID-19 than others Prevalence of and Trends in Diabetes Among Adults in the United States Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis Prevalence of prediabetes in England from 2003 to 2011: population-based, cross-sectional study Prediabetes: moving away from a glucocentric definition Conflict of interest: The authors declare no conflict of interest.Funding: The authors received no funding from an external source.